, /PRNewswire/ -- Saluda Medical, Inc., a commercial-stage medical device company focused on developing treatments for chronic neurological conditions driven by a novel closed-loop, dose-control neuromodulation platform, today announced the recent presentations of two abstracts analyzing biomarker-based spinal cord stimulation (SCS) data at the American Society of Pain and Neuroscience (ASPN) 2024 Annual Conference, held , in The abstracts, which were among 10 total abstracts with Saluda Medical clinical data presented at ASPN, relied on evidence from patients treated with the Evoke System in clinical studies. Key takeaways from these two abstracts demonstrate the significance of objective neurophysiological measurements in SCS with evoked compound action potential (ECAP) dose-controlled closed-loop therapy.
"Saluda's scientific presence at this year's ASPN conference is reflective of our commitment to elevate SCS therapy with best-in-class clinical evidence grounded in real world data and our double-blinded EVOKE RCT, and we sincerely thank our clinical investigators and their patients," said , President and CEO of Saluda Medical. "These two abstracts, highlighting biomarker-based measurements, in particular are significant to the field of SCS. We believe that the Evoke System's ability to objectively measure and respond to these neurophysiological metrics allows it to improve the reliability and reproducibility of patient outcomes from the trial period through the long-term.
